Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Descriptor ID |
D017326
|
MeSH Number(s) |
E05.318.760.250.500.220 N05.715.360.775.088.500.220 N06.850.520.450.250.250.220
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in this website by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 0 | 2 | 2 |
2005 | 0 | 1 | 1 |
2009 | 0 | 5 | 5 |
2010 | 0 | 2 | 2 |
2011 | 0 | 2 | 2 |
2013 | 1 | 1 | 2 |
2014 | 0 | 2 | 2 |
2015 | 0 | 1 | 1 |
2016 | 0 | 8 | 8 |
2017 | 0 | 5 | 5 |
2018 | 1 | 5 | 6 |
2019 | 1 | 3 | 4 |
2020 | 0 | 3 | 3 |
2021 | 1 | 2 | 3 |
2022 | 0 | 6 | 6 |
2023 | 0 | 2 | 2 |
2024 | 0 | 1 | 1 |
2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
-
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025 Mar-Apr; 75(2):141-167.
-
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials. J Infect Dis. 2024 Dec 16; 230(6):1384-1389.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clin Cancer Res. 2024 Oct 15; 30(20):4791-4799.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials. Int J Radiat Oncol Biol Phys. 2024 Dec 01; 120(5):1239-1244.
-
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024 Sep 26; 391(12):1159-1162.
-
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11?+?17/18?mutations. Future Oncol. 2024; 20(27):1973-1982.
-
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024 Aug; 9(8):103663.